AND No clinical response following treatment with prolonged plasma exchange and/or at least 2 Immunosuppressant agents Script advising that Ig therapy should be used Ig therapy for steroid resistant NMOSD is recommended to be used in combination with immunosuppressant as combination therapy medications. Review Acute relapse of NMOSD with significant disability and Review is not required for the first indication Criteria as one-off treatment is given. Outcome corticosteroids and/or plasmapheresis have failed, are contraindicated or unavailable measures have been defined. Review is not mandated for this condition. Clinical effectiveness of Ig therapy can be demonstrated by: Post Ig treatment improvement in the severity of symptoms and degree of disability as assessed by EDSS compared to Once a patient has qualified for Ig therapy to the qualifying assessment treat relapse, initial review at six months will confirm that a clinical response has been Further significant relapse post Ig therapy with significant disability demonstrated by improvement in symptoms and resistant to corticosteroids and other immunosuppressant compared to the qualifying assessment and as agents assessed by an increase in EDSS Score of at least one full point. Review by a Neurologist is required within 6 months of treatment and six monthly thereafter. Documentation of clinical effectiveness is necessary for continuation of Ig therapy. On review of the initial authorisation period Clinical effectiveness of Ig therapy can be demonstrated by:
AND No clinical response following treatment with prolonged plasma exchange and/or at least 2 Immunosuppressant agents Ig therapy for steroid resistant NMOSD is recommended to be used as combination therapy Script advising that Ig therapy should be used in combination with immunosuppressant medications. Review Criteria Acute relapse of NMOSD with significant disability and corticosteroids and/or plasmapheresis have failed, are contraindicated or unavailable Review is not mandated for this condition. Clinical effectiveness of Ig therapy can be demonstrated by: Post Ig treatment improvement in the severity of symptoms and degree of disability as assessed by EDSS compared to the qualifying assessment Further significant relapse post Ig therapy with significant disability and resistant to corticosteroids and other immunosuppressant agents Review by a Neurologist is required within 6 months of treatment and six monthly thereafter. Documentation of clinical effectiveness is necessary for continuation of Ig therapy. On review of the initial authorisation period Clinical effectiveness of Ig therapy can be demonstrated by: Review is not required for the first indication as one-off treatment is given. Outcome measures have been defined. Once a patient has qualified for Ig therapy to treat relapse, initial review at six months will confirm that a clinical response has been demonstrated by improvement in symptoms compared to the qualifying assessment and as assessed by an increase in EDSS Score of at least one full point.
Neuromyelitis-optica-spectrum-disorders-%28previously-known-as-Devic-disease%292017.docx